Literature DB >> 8873298

Medical complications of new antipsychotic drugs.

D Umbricht1, J M Kane.   

Abstract

Although antipsychotic drugs have a high therapeutic index (ratio of clinical benefit to adverse effects), they are associated with a range of adverse effects in most patients. The majority of these side effects are tolerable, readily managed, and not life threatening. The most troublesome side effects are neurological. Two new antipsychotics (clozapine and risperidone) have recently been introduced and are the first of a new generation of compounds that may further improve the therapeutic index of routine antipsychotic drug administration. Clozapine clearly has a reduced risk of drug-induced parkinsonism, akathisia, and tardive dyskinesia, while producing an increased risk of agranulocytosis, seizures, and weight gain. Risperidone at low doses produces relatively few parkinsonian side effects, but it can cause tardive dyskinesia (though relative risk remains to be established). Risperidone has not been associated with blood dyscrasias or increased risk of seizures, but weight gain can be a problem for some patients. Neuroleptic malignant syndrome has been reported with both drugs, but relative risk has not been established.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873298     DOI: 10.1093/schbul/22.3.475

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  9 in total

Review 1.  The increasing frequency of mania and bipolar disorder: causes and potential negative impacts.

Authors:  Sean H Yutzy; Chad R Woofter; Christopher C Abbott; Imad M Melhem; Brooke S Parish
Journal:  J Nerv Ment Dis       Date:  2012-05       Impact factor: 2.254

2.  Extrapyramidal side-effects of antipsychotics in a randomised trial.

Authors:  Del D Miller; Stanley N Caroff; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2008-10       Impact factor: 9.319

Review 3.  Pharmacological treatment of psychotic agitation.

Authors:  Glenn W Currier; Adam Trenton
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 5.  Treatment of psychosis in Parkinson's disease: safety considerations.

Authors:  Hubert H Fernandez; Martha E Trieschmann; Joseph H Friedman
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  Pharmacokinetic patterns of risperidone-associated adverse drug reactions.

Authors:  Georgios Schoretsanitis; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Koen R J Schruers; Sebastian Walther; Sarah E Lammertz; Ekkehard Haen; Michael Paulzen
Journal:  Eur J Clin Pharmacol       Date:  2016-07-04       Impact factor: 2.953

7.  Drug Treated Schizophrenia, Schizoaffective and Bipolar Disorder Patients Evaluated by qEEG Absolute Spectral Power and Mean Frequency Analysis.

Authors:  Richard Wix-Ramos; Xiomara Moreno; Eduardo Capote; Gilbert González; Ezequiel Uribe; Antonio Eblen-Zajjur
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-04-24       Impact factor: 2.582

8.  Health Education and Activity - Lessening The Inequalities in mental health (HEA - LTI mental health).

Authors:  Georgia Richmond; Conor Kenny; Jabed Ahmed; Lucy Stephenson; Jamie Lindsay; Patrick Earls; Donncha Mullin; Howard Ryland
Journal:  BMJ Qual Improv Rep       Date:  2017-02-09

9.  G-protein beta3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients.

Authors:  Young-Min Park; Young-Cho Chung; Seung-Hwan Lee; Kang-Joon Lee; Hyun Kim; Jung-Eun Choi; Seung-Gul Kang; Min-Soo Lee; Leen Kim; Heon-Jeong Lee
Journal:  Psychiatry Investig       Date:  2009-03-31       Impact factor: 2.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.